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General topic: 
Supply chain models and their analysis for autologous cell 
therapy manufacturing and distribution
Objectives:
 Safety: Safe cell therapy products
 Efficacy: Cell therapy products with high level of efficacy
 Cost: Reduce total manufacturing logistics costs and cost to the 
patient
 Risk: Reduce the risk of patient morbidity and mortality 
(reduce fulfillment time and fulfillment time variability)
 Patient access: Increase patient access through network design
Overview
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Exemplar: CAR-T cells
Partners: Georgia Tech, Univ of Wisconsin-Madison, Univ of 
Pennsylvania
Deliverable: simulation/optimization-based decision support 
tools for “WHAT-IF” analysis
 Single manufacturing facility (building block)
 Supply chain network: facilities, suppliers, and clinics
Overview
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Alternative supply chain design strategies 
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 Network design: 
 How many facilities, facility locations, determining what 
facilities provide service to which clinics
 Reagent supply disruption analysis
 Supply chain operations & patient health:
 Specimen queuing policy (FIFO, priority)
 Impact on manufacturing and QC sub-processes
 Inventory policy
 Number of bioreactors
 Number of operators
Issues addressed & to be addressed
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 Applications
o Evaluate supply chain design models for cell therapy manufacturing and distribution
o Simulate unexpected events, such as reagent supply disruptions, and estimate the risks 
associated with these events
o Assess risk mitigation strategies
 Representative strategies to mitigate unexpected supply disruptions
o Buffer stock of reagents
o Multiple suppliers for key reagents
o Capability of rapidly ramping up supplies and production
o Trans-shipment of orders, bioreactors, reagents, etc.
 Decisions that can be supported by the simulation toolset
o Time to restore the original steady state
o Average increased queue time
o Order reject rate
o Implementation cost
Applications of the Simulation Toolset
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How base stock level influences cancelled rate
 Cancelled rate versus base stock 
level
 Run 10 simulations at 6 different 
base stock levels
 Record average cancelled rate at 
T=1000
 as we increase base stock level, 
cancelled rate decreases
[# of Bioreactor fixed at 10, fastest 
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 Case study motivation
o Visit to UPenn revealed another challenge – supply disruption
o Small number of suppliers for some key reagents
o Switching suppliers may need FDA re-approval => barrier to supplier risk 
mitigation
 Case study description
o Single reagent
o Two month disruption in reagent supply
o Objectives: to understand the impact of supply disruptions and how to 
recover from them
 Compare three scenarios
o Single supplier, single production facility – multiple cases
o Two suppliers, one production facility
o Two suppliers, two production facilities that allow transferring orders
Supply Disruption Case Study
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 Patients per year: 250
 Bioreactors: 10
 Operators: 6
 Stationary operating condition: 
base stock level = 100, days 1-500
Single facility, no disruption case
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 Patients per year: 250
 Bioreactors: 10
 Operators: 6
 Base stock level = 100, days 1-200
 Base stock level = 0, days 201-260
 Base stock level = 100, days 261-500
60-day disruption case
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60-day disruption: bioreactors: 11, operators: 6
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60-day disruption: bioreactors: 10, operators: 7
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60-day disruption: bioreactors: 11, operators: 7
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60-day disruption: bioreactors: 12, operators: 7
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60-day disruption: bioreactors: 15, operators: 9
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60-day disruption: bioreactors: 20, operators: 12
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Simulation model used to evaluate two network designs for mitigating 
supply disruption risks
Network design for risk mitigation
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 Risks:
 Patient may not survive before therapy becomes available
 Therapy may not be effective
 Therapy may be contaminated
 For a given patient, what is the best ‘balance’ of these risks in order 
to minimize total mortality risk?  When should manufacturing and 
QC processes be accelerated and by how much?
 What R&D investments would have the greatest impact in reducing 
these risks?
Patient health based manufacturing
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 Disruption recovery can require surge capability that is not needed 
in steady state operations
 Surge capability occurs at several levels: reagent supply, 
bioreactors, skilled staff
 Network designs that allow for transshipment of reagents and 
specimens can pool and hence mitigate the risk of a supplier 
disruption
 Next steps – patient health-based manufacturing
Summary
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